BioCentury | Jan 8, 2020
Finance

With $69M D round, Adagene looks to Phase II for solid, blood cancers

...for the four other candidates in its pipeline, including a Phase I antibody out-licensed to Guilin Sanjin Pharmaceutical Co. Ltd....
Items per page:
1 - 1 of 1
BioCentury | Jan 8, 2020
Finance

With $69M D round, Adagene looks to Phase II for solid, blood cancers

...for the four other candidates in its pipeline, including a Phase I antibody out-licensed to Guilin Sanjin Pharmaceutical Co. Ltd....
Items per page:
1 - 1 of 1